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Background
Combined BRAF and MEK inhibition may delay the onset
of resistance compared with BRAF inhibition alone. The
safety and tolerability of the BRAF and MEK inhibitors,
vemurafenib and cobimetinib were evaluated in a phase
1B trial, BRIM7 (NCT01271803). Modulation of signaling
pathways, transcriptional outputs and T-cell dynamics
were assessed in tumor samples obtained from BRIM7.
Materials and methods
Tumor tissues were collected at baseline prior to treat-
ment, on-treatment at cycle 1 day 14 (C1D14) and at dis-
ease progression (PD). Modulation of the MAPK and PI3K
pathways, cell proliferation, and CD8+ T-cells in tumor
biopsies were assessed by immunohistochemistry. Changes
in transcription profiles upon treatment were measured by
qRT-PCR using the Fluidigm/Nanostring platforms.
Results
133 tumor samples have been collected representing 82
unique patients. There are six paired biopsies (baseline and
C1D14) from the same patients, and seven evaluable PD
samples. In the six paired biopsies (baseline and C1D14),
robust inhibition of the MAPK pathway was observed in
tumors following vemurafenib + cobimetinib treatment as
measured by reduction of pERK levels compared to base-
line (mean H-score inhibition 88 +/- 12%). This was
observed in samples from BRAF inhibitor-naïve patients
(n=2) and also from patients who had progressed while on
vemurafenib (n=4). The inhibition of pERK correlated with
the reduction of the proliferation marker Ki67 in C1D14
tumor samples (77 +/- 10%), while inhibition of the PI3K
pathway marker pS6 showed greater variability (68 +/-
28%). At PD, varying levels of MAPK pathway activity and
moderate-to-high expression of Ki67 were seen in tumors.
Ongoing analyses of combination treatment effects on the
MAPK pathway, immune regulatory gene transcription
and CD8+T-cell status will be presented.
Conclusions
The combination of vemurafenib + cobimetinib results
in MAPK pathway inhibition in both BRAF inhibitor
naïve patients and patients who have progressed on
vemurafenib. Increased levels of pERK and Ki67 at PD
suggest the renewal of proliferation as tumors may have
escaped the inhibitory effects of the combination ther-
apy. Effects of the combined treatment on the MAPK
pathway and immune gene signatures will also be
discussed.
Authors’ details
1Genentech, South San Francisco, CA, USA. 2Peter MacCallum Cancer Centre,
East Melbourne, Victoria, Australia. 3The Angeles Clinic and Research Institute,
Los Angeles, CA, USA. 4Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
5University of Colorado Comprehensive Cancer Center, Aurora, CO, USA.
6University of Chicago, Chicago, USA. 7The Jonsson Comprehensive Cancer
Center at University of California, Los Angeles, CA, USA.
* Correspondence: ARibas@mednet.ucla.edu
7The Jonsson Comprehensive Cancer Center at University of California, Los
Angeles, CA, USA
Full list of author information is available at the end of the article
Yan et al. Journal of Translational Medicine 2014, 12(Suppl 1):O12
http://www.translational-medicine.com/content/12/S1/O12
© 2014 Yan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 6 May 2014
doi:10.1186/1479-5876-12-S1-O12
Cite this article as: Yan et al.: Biomarker analysis of on-treatment and at
progression biopsies from BRIM7 - a phase 1B trial of combined
vemurafenib and cobimetinib treatment in BRAF V600 mutated
melanoma. Journal of Translational Medicine 2014 12(Suppl 1):O12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yan et al. Journal of Translational Medicine 2014, 12(Suppl 1):O12
http://www.translational-medicine.com/content/12/S1/O12
Page 2 of 2
